Sepsis is the tenth leading cause of death in the United States (Hoyert et al. 2001) and has a mortality rate of up to 70% (Angus et al. 2001; Annane et al. 2003). Inpatients with sepsis have a 26-fold increased risk of death compared to intensive care unit subjects without sepsis (Annane et al. 2003). New medications are urgently needed to prevent and treat sepsis since only a few new classes of antibiotics have been added to the armamentarium in the past ten years, and only one new class of medication specifically targeting sepsis (drotrecogin-alfa) has been added (Bernard et al. 2001).
Recently, several classes of medications including HMG-CoA reductase inhibitors (statins) have been found to attenuate the systemic inflammatory response (de Bont et al. 1998; Jialal et al. 2001; Musial et al. 2001; Ridker et al. 1998; Rosenson and Tangney 1998; Rosenson et al. 1999; Strandberg et al. 1999). In addition, statins have been demonstrated to have protective endothelial effects, influence inflammatory cell signaling, directly effect T-cell activity, and influence the nitric oxide balance to promote hemodynamic stability (Almog 2003; Hothersall et al. 2006; Terblanche et al. 2007). Several epidemiologic studies have demonstrated that subjects receiving statins hospitalized with bacteremia and community-acquired pneumonia have improved clinical outcomes, or decreased incidence of sepsis (Almog et al. 2004, 2007; Fernandez et al. 2006; Frost et al. 2007; Gupta et al. 2007; Hackam et al. 2006; Kruger et al. 2006; Liappis et al. 2001; Martin et al. 2007; Mortensen et al. 2005a,b; Schlienger et al. 2007; Thomsen et al. 2006; Yang et al. 2007).
The purpose of this article is to review the scientific literature regarding the potential role of statins in the prevention and/or treatment of severe sepsis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Almog, Y. (2003). Statins, inflammation, and sepsis: Hypothesis. Chest, 124, 740–743.
Almog, Y., Shefer, A., Novack, V., Maimon, N., Barski, L., Eizinger, M., Friger, M., Zeller, L., and Danon, A. (2004). Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation, 110, 880–885.
Almog, Y., Novack, V., Eisinger, M., Porath, A., Novack, L., and Gilutz, H. (2007). The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med, 35, 372–378.
Ando, H., Takamura, T., Ota, T., Nagai, Y., and Kobayashi, K. (2000). Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther, 294, 1043–1046.
Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M.R. (2001a). Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med, 29, 1303–1310.
Annane, D., Aegerter, P., Jars-Guincestre, M.C., and Guidet, B. (2003). Current epidemiology of septic shock: The CUB-Rea network. Am J Respir Crit Care Med, 168, 165–172.
Arntz, H.R. (1999). Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events. Atherosclerosis, 147 Suppl 1, S17–S21.
Aviram, M., Rosenblat, M., Bisgaier, C.L., and Newton, R.S. (1998). Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis, 138, 271–280.
Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., and Fisher, C.J., Jr. (2001). Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 344, 699–709.
Bickel, C., Rupprecht, H.J., Blankenberg, S., Espinola-Klein, C., Rippin, G., Hafner, G., Lotz, J., Prellwitz, W., and Meyer, J. (2002). Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol, 82, 25–31.
Bonville, D.A., Parker, T.S., Levine, D.M., Gordon, B.R., Hydo, L.J., Eachempati, S.R., and Barie, P.S. (2004). The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome. Surg Infect (Larchmt), 5, 39–49.
Bourcier, T., and Libby, P. (2000). HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol, 20, 556–562.
Cazzola, M., Matera, M.G., and Pezzuto, G. (2005). Inflammation – A new therapeutic target in pneumonia. Respiration, 72, 117–126.
Claxton, A.J., Jacobs, D.R., Jr., Iribarren, C., Welles, S.L., Sidney, S., and Feingold, K.R. (1998). Association between serum total cholesterol and HIV infection in a high-risk cohort of young men. J Acquir Immune Defic Syndr Hum Retrovirol, 17, 51–57.
de Bont, N., Netea, M.G., Rovers, C., Smilde, T., Demacker, P.N., van der Meer, J.W., and Stalenhoef, A.F. (1998). LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis, 139, 147–152.
Dichtl, W., Dulak, J., Frick, M., Alber, H.F., Schwarzacher, S.P., Ares, M.P., Nilsson, J., Pachinger, O., and Weidinger, F. (2003). HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 23, 58–63.
Diomede, L., Albani, D., Sottocorno, M., Donati, M.B., Bianchi, M., Fruscella, P., and Salmona, M. (2001). In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol, 21, 1327–1332.
Fernandez, R., De Pedro, V.J., and Artigas, A. (2006). Statin therapy prior to ICU admission: Protection against infection or a severity marker? Intensive Care Med, 32, 160–164.
Frost, F.J., Petersen, H., Tollestrup, K., and Skipper, B. (2007). Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest, 131, 1006–1012.
Girona, J., La Ville, A.E., Sola, R., Plana, N., and Masana, L. (1999). Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol, 83, 846–851.
Grip, O., Janciauskiene, S., and Lindgren, S. (2002). Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res, 51, 58–62.
Grosser, N., Erdmann, K., Hemmerle, A., Berndt, G., Hinkelmann, U., Smith, G., and Schroder, H. (2004). Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun, 325, 871–876.
Gupta, R., Plantinga, L.C., Fink, N.E., Melamed, M.L., Coresh, J., Fox, C.S., Levin, N.W., and Powe, N.R. (2007). Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA, 297, 1455–1464.
Hackam, D.G., Mamdani, M., and Redelmeier, D.A. (2006). Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet, 367, 413–418.
Hakamada-Taguchi, R., Uehara, Y., Kuribayashi, K., Numabe, A., Saito, K., Negoro, H., Fujita, T., Toyo-oka, T., and Kato, T. (2003). Inhibition of hydroxymethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res, 93, 948–956.
Harris, H.W., Gosnell, J.E., and Kumwenda, Z.L. (2000). The lipemia of sepsis: Triglyceride-rich lipoproteins as agents of innate immunity. J Endotoxin Res, 6, 421–430.
Hothersall, E., McSharry, C., and Thomson, N.C. (2006). Potential therapeutic role for statins in respiratory disease. Thorax, 61, 729–734.
Hoyert, D.L., Arias, E., and Smith, B.L. (2001). Deaths: Final data for 1999. Natl Vital Stat Rep, 49, 1–113.
Ikeda, U., and Shimada, K. (1999). Statins and monocytes. Lancet, 353, 2070.
Ikeda, U., Ito, T., and Shimada, K. (1999). Statins and C-reactive protein. Lancet, 353, 1274–1275.
Iribarren, C., Jacobs, D.R., Jr., Sidney, S., Claxton, A.J., and Feingold, K.R. (1998). Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect, 121, 335–347.
Jacobson, J.R., Barnard, J.W., Grigoryev, D.N., Ma, S.F., Tuder, R.M., and Garcia, J.G. (2005). Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol, 288, L1026–L1032.
Jialal, I., Stein, D., Balis, D., Grundy, S.M., Adams-Huet, B., and Devaraj, S. (2001). Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 103, 1933–1935.
Kallen, J., Welzenbach, K., Ramage, P., Geyl, D., Kriwacki, R., Legge, G., Cottens, S., Weitz-Schmidt, G., and Hommel, U. (1999). Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol, 292, 1–9.
Kimura, M., Kurose, I., Russell, J., and Granger, D.N. (1997). Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol, 17, 1521–1526.
Kleemann, R., Verschuren, L., de Rooij, B.J., Lindeman, J., de Maat, M.M., Szalai, A.J., Princen, H.M., and Kooistra, T. (2004). Evidence for anti-inflammatory activity of statins and PPAR alpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood, 103, 4188–4194.
Koenig, W. (2000). Heart disease and the inflammatory response. BMJ, 321, 187–188.
Kothe, H., Dalhoff, K., Rupp, J., Muller, A., Kreuzer, J., Maass, M., and Katus, H.A. (2000). Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae. Circulation, 101, 1760–1763.
Kruger, P., Fitzsimmons, K., Cook, D., Jones, M., and Nimmo, G. (2006). Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med, 32, 75–79.
Landmesser, U., Bahlmann, F., Mueller, M., Spiekermann, S., Kirchhoff, N., Schulz, S., Manes, C., Fischer, D., de Groot, K., Fliser, D., Fauler, G., Marz, W., and Drexler, H. (2005). Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation, 111, 2356–2363.
Lefer, D.J., Scalia, R., Jones, S.P., Sharp, B.R., Hoffmeyer, M.R., Farvid, A.R., Gibson, M.F., and Lefer, A.M. (2001). HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J, 15, 1454–1456.
Liappis, A.P., Kan, V.L., Rochester, C.G., and Simon, G.L. (2001). The effect of statins on mortality in patients with bacteremia. Clin Infect Dis, 33, 1352–1357.
Majumdar, S.R., McAlister, F.A., Eurich, D.T., Padwal, R.S., and Marrie, T.J. (2006). Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ, 333, 999.
Martin, C.P., Talbert, R.L., Burgess, D.S., and Peters, J.I. (2007). Effectiveness of statins in reducing the rate of severe sepsis: A retrospective evaluation. Pharmacotherapy, 27, 20–26.
Mortensen, E.M., Restrepo, M., Anzueto, A., and Pugh, J. (2005a). The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res, 6, 82.
Mortensen, E.M., Restrepo, M.I., Copeland, L.A., Pugh, M.J., and Anzueto, A. (2006). Statins and outcomes in patients with pneumonia: Not only healthy user bias. BMJ, 333, 1123–1124.
Musial, J., Undas, A., Gajewski, P., Jankowski, M., Sydor, W., and Szczeklik, A. (2001). Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol, 77, 247–253.
Nath, N., Giri, S., Prasad, R., Singh, A.K., and Singh, I. (2004). Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol, 172, 1273–1286.
Nathan, C. (2002). Points of control in inflammation. Nature, 420, 846.
Newton, C.J., Ran, G., Xie, Y.X., Bilko, D., Burgoyne, C.H., Adams, I., Abidia, A., McCollum, P.T., and Atkin, S.L. (2002). Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol, 174, 7–16.
Ni, W., Egashira, K., Kataoka, C., Kitamoto, S., Koyanagi, M., Inoue, S., and Takeshita, A. (2001). Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res, 89, 415–421.
Pruefer, D., Makowski, J., Schnell, M., Buerke, U., Dahm, M., Oelert, H., Sibelius, U., Grandel, U., Grimminger, F., Seeger, W., Meyer, J., Darius, H., and Buerke, M. (2002). Simvastatin inhibits inflammatory properties of staphylococcus aureus alpha-toxin. Circulation, 106, 2104–2110.
Rice, J.B., Stoll, L.L., Li, W.G., Denning, G.M., Weydert, J., Charipar, E., Richenbacher, W.E., Miller, F.J., Jr., and Weintraub, N.L. (2003). Low-level endotoxin induces potent inflammatory activation of human blood vessels: Inhibition by statins. Arterioscler Thromb Vasc Biol, 23, 1576–1582.
Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F.M., Moye, L.A., Goldman, S., Flaker, G.C., and Braunwald, E. (1998). Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (care) investigators. Circulation, 98, 839–844.
Rikitake, Y., Kawashima, S., Takeshita, S., Yamashita, T., Azumi, H., Yasuhara, M., Nishi, H., Inoue, N., and Yokoyama, M. (2001). Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis, 154, 87–96.
Romano, M., Diomede, L., Sironi, M., Massimiliano, L., Sottocorno, M., Polentarutti, N., Guglielmotti, A., Albani, D., Bruno, A., Fruscella, P., Salmona, M., Vecchi, A., Pinza, M., and Mantovani, A. (2000). Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest, 80, 1095–1100.
Rosenson, R.S., and Tangney, C.C. (1998). Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA, 279, 1643–1650.
Rosenson, R.S., Tangney, C.C., and Casey, L.C. (1999). Inhibition of proinflammatory cytokine production by pravastatin. Lancet, 353, 983–984.
Ross, R. (1999). Ahterosclerosis – an inflammatory disease. N Engl J Med, 340, 115–126.
Rudich, S.M., Mongini, P.K., Perez, R.V., and Katznelson, S. (1998). HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human b-lymphocyte activation. Transplant Proc, 30, 992–995.
Scalia, R., Gooszen, M.E., Jones, S.P., Hoffmeyer, M., Rimmer, D.M., III, Trocha, S.D., Huang, P.L., Smith, M.B., Lefer, A.M., and Lefer, D.J. (2001). Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation, 103, 2598–2603.
Schlienger, R.G., Fedson, D.S., Jick, S.S., Jick, H., and Meier, C.R. (2007). Statins and the risk of pneumonia: A population-based, nested case-control study. Pharmacotherapy, 27, 325–332.
Shi, J., Wang, J., Zheng, H., Ling, W., Joseph, J., Li, D., Mehta, J.L., Ponnappan, U., Lin, P., Fink, L.M., and Hauer-Jensen, M. (2003). Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis, 14, 575–585.
Shishehbor, M.H., Brennan, M.L., Aviles, R.J., Fu, X., Penn, M.S., Sprecher, D.L., and Hazen, S.L. (2003). Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation, 108, 426–431.
Steiner, S., Speidl, W.S., Pleiner, J., Seidinger, D., Zorn, G., Kaun, C., Wojta, J., Huber, K., Minar, E., Wolzt, M., and Kopp, C.W. (2005). Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation, 111, 1841–1846.
Strandberg, T.E., Vanhanen, H., and Tikkanen, M.J. (1999). Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet, 353, 118–119.
Terblanche, M., Almog, Y., Rosenson, R.S., Smith, T.S., and Hackam, D.G. (2007). Statins and sepsis: Multiple modifications at multiple levels. Lancet Infect Dis, 7, 358–368.
Thomsen, R.W., Hundborg, H.H., Johnsen, S.P., Pedersen, L., Sorensen, H.T., Schonheyder, H.C., and Lervang, H.H. (2006). Statin use and mortality within 180 days after bacteremia: A population-based cohort study. Crit Care Med, 34, 1080–1086.
Vincent, J.L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P.M., Sprung, C.L., Colardyn, F., and Blecher, S. (1998). Use of the sofa score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on “Sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med, 26, 1793–1800.
Wang, H.R., Li, J.J., Huang, C.X., and Jiang, H. (2005). Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappa b in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta, 353, 53–60.
Weis, M., Pehlivanli, S., Meiser, B.M., and von Scheidt, W. (2001). Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol, 38, 814–818.
Yamamoto, A., Hoshi, K., and Ichihara, K. (1998). Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol, 361, 143–149.
Yang, K.C., Chien, J.Y., Tseng, W.K., Hsueh, P.R., Yu, C.J., and Wu, C.C. (2007). Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med, 25, 494–501.
Yoshida, M., Sawada, T., Ishii, H., Gerszten, R.E., Rosenzweig, A., Gimbrone, M.A., Jr., Yasukochi, Y., and Numano, F. (2001). HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol, 21, 1165–1171.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag
About this chapter
Cite this chapter
Mortensen, E.M., Restrepo, M.I., Anzueto, A. (2008). The Potential Role of Statins in Severe Sepsis. In: Rello, J., Restrepo, M.I. (eds) Sepsis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79001-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-540-79001-3_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79000-6
Online ISBN: 978-3-540-79001-3
eBook Packages: MedicineMedicine (R0)